JPRN-jRCT1080223601已完成未知
A Multicenter Observational Study Evaluating the Effectiveness of Recombinant Coagulation factor VIII Fc Fusion protein (rFVIIIFc) in Adolescents and Children with Hemophilia under real world clinical setting in Japan
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Sanofi K.K.
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 至 <= 17age old（—）
- 性别
- All
入选标准
- •Patients with hemophilia A with any severity and treated with rFVIIIFc
- •Detailed criteria are described in the protocol.
- •Patients less than 18 years of age with hemophilia A with any severity and treated with rFVIIIFc. (include over 18 years patients in part 2 study)
- •Part 1 study: general pediatric study
- •Part 2 study: inhibitor positive patient diagnosed by the treating physician
排除标准
- •Candidates will be excluded from study entry if any of the following exclusion criteria exist.
- •1.Patients to whom Informed consent cannot be conducted or who have no willingness to provide informed consent
- •2.Those with other bleeding disorder than hemophilia A
- •3.Patients 18 years of age and older at entry (part 1 study)
研究者
相似试验
尚未招募
Unknown
Effect of Sucralfate as a prophylactic agent for stress ulcer in ICU settingsCTRI/2024/01/061168Fourrts India Laboratories Pvt Ltd
进行中（未招募）
4 期
A clinical trial to study the effect of Evogliptin in patients with type 2 diabetes mellitus.CTRI/2019/10/021542Alkem Laboratories Limited
进行中（未招募）
1 期
A multi-centre exploratory study to evaluate the efficacy of the dopamine receptor agonist rotigotine in the treatment of hemispatial neglect and motor deficits following stroke. - A dopamine agonist for hemispatial neglect and motor deficits following stroke.Hemispatial neglect and motor deficits following right-hemisphere stroke.MedDRA version: 9.1 Level: LLT Classification code 10042244 Term: StrokeEUCTR2006-006949-13-GBniversity College London20
招募中
不适用
HIF_PHi studyJPRN-jRCT1051210196Minamino Tohru50
尚未招募
Unknown
A multicenter observational study to evaluate the efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with unresectable neuroendocrine tumors (NEN).JPRN-UMIN000054127ational cancer center200